Last reviewed · How we verify
NCT04326309
Audio Data Collection for Identification and Classification of Coughing
trial in COVID-19 in 336 participants. Completed in 24 January 2022.
24 January 2022
Quick facts
| Lead sponsor | HealthMode Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 336 |
| Start date | 25 March 2020 |
| Primary completion | 24 January 2022 |
| Estimated completion | 24 January 2022 |
| Sites | 1 location across United States |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Coronavirus Infections — all drugs for Coronavirus Infections →
- Hay Fever — all drugs for Hay Fever →
- Asthma — all drugs for Asthma →
Sponsor
HealthMode Inc.
Who can join
18 and older, any sex, with COVID-19 or Coronavirus Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).
Verma HK, Merchant N, Verma MK, Kuru Cİ, et al · · 2020 · cited 21× · PMID 32792167 · DOI 10.1016/j.bj.2020.07.008
Verify or expand the search:
- PubMed search for NCT04326309
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other HealthMode Inc. trials
Trials by the same sponsor.
- NCT04675853 — Rapid dEvice Testing pROtocol for Parkinson's Disease · completed
- NCT04413851 — Feasibility of Passive Data Collection in Dementia Subjects With Agitation · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04326309 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HealthMode Inc.
- Last refreshed: 29 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04326309.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing